-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
-
Dr. Fred R. Hirsch Departs IASLC CEO Role, Joins Mount Sinai Hospital
Posted: December 2018 Fred R. Hirsch, MD, resigned from his position of IASLC CEO at the end of October and has joined Mount Sinai Hospital in New York City as the executive director for the Clinical Lung Cancer Institute and Endowed Professor at the Icahn Medical School, Mount Sinai, where he will be facilitating basic…
-
Prophylactic Cranial Irradiation in Locally Advanced NSCLC Falls Flat
By John Armstrong, MD, FRCPI, DABR, FFRRCSI Posted: December 2018 RTOG 0214, a phase III randomized trial, is the biggest trial to date testing prophylactic cranial irradiation (PCI) in locally advanced NSCLC.1 The trial, presented at the IASLC World Conference on Lung Cancer this past September, evaluated patients with stage III NSCLC whose disease had…
-
FDA Approval Processes in the Era of Targeted Therapies: A Conversation with Dr. Richard Pazdur
Posted: December 2018 Richard Pazdur, MD, is director of the U.S. Food and Drug Administration’s (FDA’s) Oncology Center of Excellence. Below, he discusses the current status of and future directions for the FDA’s approval of oncology drugs. Q: Has the accelerated conditional approval process been a success in your view? Are there aspects you would…
-
Explaining IMpower132: An Interview with Dr. Vassiliki A. Papadimitrakopoulou
Posted: December 2018 In the following interview, Vassiliki A. Papadimitrakopoulou, MD, Jay and Lori Eisenberg Distinguished Professor of Medicine and section chief of Thoracic Medical Oncology at the University of Texas MD Anderson Cancer Center, discusses the findings and implications of IMpower132. Q: Please explain the findings of IMpower132.A: IMpower132 was a global, randomized, open-label,…
-
The Future Is Now: Pathology Is Going Digital
By Sanja Dacic, MD, PhD, and Douglas J. Hartman, MD Posted: December 2018 The pathology community initially showed resistance to digital pathology implementation in routine practice mostly because of pathologists’ lack of experience with the ever-changing technology, traditional thinking that review of digital images is more time consuming than light microscopy, and lack of approval…
-
Targeted Therapy Plus Immune Checkpoint Inhibitors: Research Opportunities, But No Improvement in Activity to Date
By Ross Soo, MB BS, PhD, FRACP Posted: December 2018 The treatment of patients with advanced NSCLC harbouring an actionable oncogene with tyrosine kinase inhibitors (TKIs) directed at its oncogenic molecular alteration represents one of the most significant advances in lung cancer management. Another area of achievement in the treatment of advanced NSCLC has been…
-
The State of Lung Cancer in Egypt: Progress Is at Hand
By C.A.I.R.O Journal Club Executive Board Posted: December 2018 Egypt faced major turmoil in 2011, with subsequent dramatic political changes and a rapidly developing economic crises that, within a few months, led to a significant increase in the proportion of the population living below the poverty line. As per the World Bank, Egypt is defined…
-
Neoadjuvant Nivolumab Shows Unprecedented Pathologic Complete Response for Stage III NSCLC
By Mariano Provencio-Pulla, MD, PhD Posted: December 2018 Patients with stage IIIA NSCLC with clinically evident N2 nodal spread have an overall 5-year survival rate of only 10% to 15%. The aims of therapy in stage III disease are to increase both locoregional and systemic control of the disease. Because distant metastases remain the major…
-
NCI Corner: Racial Differences in the Transcriptomes of Lung Tumors
Posted: December 2018 Investigators at the National Cancer Institute (NCI) compared the transcriptional profiles of lung cancers from African American patients to those from white patients and identified molecular differences that may result in population differences in tumor biology. Researchers led by Brid M. Ryan, PhD, MPH, an investigator from the Laboratory of Human Carcinogenesis…
-
Scientific Highlights from the IASLC Latin America Conference on Lung Cancer
By Edgardo S. Santos Castillero, MD, FACP Posted: December 2018 Five abstracts were presented at the Presidential Symposium of the 2018 IASLC Latin America Conference on Lung Cancer, held in August in Córdoba, Argentina. All of the presentations centered on immunotherapy, with the following themes: (1) defining best treatment options as first-line therapy, (2) novel…
View ILCN Archives
Provider Resources
Popular Articles